A pioneering study, presented today at the EADV Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity. AMSTERDAM, Sept. 24, 2024 /PRNewswire/ — This is the first study to…